Altimmune, Inc. reports results for the quarter ended September 30 - Earnings Summary

Altimmune

12/11/2026 16:17

Altimmune, Inc. ALT.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -21 cents.  The mean expectation of ten analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -15 cents to -12 cents per share.
Reported revenue was zero​; analysts expected zero. 
Altimmune, Inc.'s reported EPS for the quarter was a loss of 15 cents​.
The company reported a quarterly loss of $31.61 million.
Altimmune, Inc. shares had fallen by 32.5% this quarter and lost 46.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Altimmune, Inc. is $15.00, about 87.1% above its last closing price of $1.93
This summary was machine generated from LSEG data November 12 at 04:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.13
-0.15
Missed
Jun. 30 2026 
-0.14
-0.12
Beat
Mar. 31 2026 
-0.25
-0.18
Beat
Dec. 31 2025 
-0.24
-0.27
Missed